Among them, PD-L1 expression, TMB (≥10 mut/Mb), microsatellite instability (MSI-H), and mismatch repair deficiency (MMR) had been approved by health regulatory agencies as predictive biomarkers for immunotherapy in patients with NSCLC (55, 59–62). This evidence concerns the gene CD274 and hyperinsulinemic hypoglycemia, familial, 4.